MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Bristol-Myers Squibb Company DSO Ratio 2011-2026 | BMY
Annual DSO Ratio Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 83.9 | 81.9 | 84.4 | 76.1 | 70.3 | 69.5 | 107 | 96.5 | 111 | 104 | 94.8 | 77.9 | 74.8 | 63.9 | 64.3 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 111 | 63.9 | 84 |
Quarterly DSO Ratio Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.6 | 88.9 | 86.1 | 81.8 | 79.8 | 84.9 | 82 | 80.2 | - | 39.1 | 32.7 | 70 | - | 71.7 | 68.9 | 70.7 | 70.1 | 73.6 | 76.6 | 68.5 | 88.3 | 117 | 112 | 104 | 89.5 | 95.6 | 95.4 | 108 | 106 | 109 | 112 | 110 | 96.5 | 103 | 104 | 102 | 91.5 | 96.4 | 94.2 | 86.8 | 72.7 | 78.9 | 79.5 | 80.8 | 69 | 75.4 | 75.7 | 76.7 | 67.1 | 75.3 | 63.3 | 59.3 | 62.6 | 63.9 | 62.9 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 117 | 32.7 | 82.8 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K |  USA |
 |
ADMA Biologics
ADMA
|
74.6 | $ 16.45 | 0.43 % | $ 3.92 B | USA |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 3.64 | -1.89 % | $ 1.09 B |  Canada |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
20.6 | $ 0.83 | 4.23 % | $ 4.53 M | China |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
ANI Pharmaceuticals
ANIP
|
114 | $ 76.75 | 0.85 % | $ 1.48 B | USA |
 |
Apellis Pharmaceuticals
APLS
|
115 | $ 19.93 | -1.14 % | $ 2.51 B | USA |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | USA |
 |
Athersys
ATHX
|
22.6 | - | 3.77 % | $ 22.4 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
47.5 | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
105 | $ 163.82 | -0.14 % | $ 8.15 B | USA |
 |
BridgeBio Pharma
BBIO
|
52.4 | $ 66.98 | 3.8 % | $ 12.8 B | USA |
 |
BioDelivery Sciences International
BDSI
|
115 | - | -4.8 % | $ 255 M | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
103 | - | -7.31 % | $ 87 M | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
88.9 | $ 60.75 | 3.79 % | $ 11.7 B | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
4.13 | $ 3.24 | 1.73 % | $ 1.16 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
Capricor Therapeutics
CAPR
|
31.9 | $ 25.71 | -0.5 % | $ 688 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
47.4 | $ 28.49 | 0.04 % | $ 1.65 B | USA |
 |
CymaBay Therapeutics
CBAY
|
182 | - | - | $ 3.45 B | USA |
 |
Avid Bioservices
CDMO
|
45.6 | - | - | $ 789 M | USA |